JP2019047818A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019047818A5 JP2019047818A5 JP2018233311A JP2018233311A JP2019047818A5 JP 2019047818 A5 JP2019047818 A5 JP 2019047818A5 JP 2018233311 A JP2018233311 A JP 2018233311A JP 2018233311 A JP2018233311 A JP 2018233311A JP 2019047818 A5 JP2019047818 A5 JP 2019047818A5
- Authority
- JP
- Japan
- Prior art keywords
- rodent
- sirpα
- gene
- human
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000283984 Rodentia Species 0.000 claims 62
- 101000863873 Homo sapiens Tyrosine-protein phosphatase non-receptor type substrate 1 Proteins 0.000 claims 56
- 102100029948 Tyrosine-protein phosphatase non-receptor type substrate 1 Human genes 0.000 claims 26
- 210000004027 cell Anatomy 0.000 claims 25
- 108700024394 Exon Proteins 0.000 claims 9
- 238000000034 method Methods 0.000 claims 9
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 230000003834 intracellular effect Effects 0.000 claims 4
- 229940000406 drug candidate Drugs 0.000 claims 3
- 206010057249 Phagocytosis Diseases 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims 2
- 230000008782 phagocytosis Effects 0.000 claims 2
- 239000000758 substrate Substances 0.000 claims 2
- 230000008685 targeting Effects 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 210000001671 embryonic stem cell Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361881261P | 2013-09-23 | 2013-09-23 | |
| US61/881,261 | 2013-09-23 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016544055A Division JP6453893B2 (ja) | 2013-09-23 | 2014-09-23 | ヒト化シグナル調節タンパク質遺伝子を有する非ヒト動物 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020026122A Division JP6875573B2 (ja) | 2013-09-23 | 2020-02-19 | ヒト化シグナル調節タンパク質遺伝子を有する非ヒト動物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019047818A JP2019047818A (ja) | 2019-03-28 |
| JP2019047818A5 true JP2019047818A5 (enExample) | 2020-02-27 |
| JP6665269B2 JP6665269B2 (ja) | 2020-03-13 |
Family
ID=51663510
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016544055A Active JP6453893B2 (ja) | 2013-09-23 | 2014-09-23 | ヒト化シグナル調節タンパク質遺伝子を有する非ヒト動物 |
| JP2018233311A Active JP6665269B2 (ja) | 2013-09-23 | 2018-12-13 | ヒト化シグナル調節タンパク質遺伝子を有する非ヒト動物 |
| JP2020026122A Active JP6875573B2 (ja) | 2013-09-23 | 2020-02-19 | ヒト化シグナル調節タンパク質遺伝子を有する非ヒト動物 |
| JP2021072857A Active JP7149370B2 (ja) | 2013-09-23 | 2021-04-22 | ヒト化シグナル調節タンパク質遺伝子を有する非ヒト動物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016544055A Active JP6453893B2 (ja) | 2013-09-23 | 2014-09-23 | ヒト化シグナル調節タンパク質遺伝子を有する非ヒト動物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020026122A Active JP6875573B2 (ja) | 2013-09-23 | 2020-02-19 | ヒト化シグナル調節タンパク質遺伝子を有する非ヒト動物 |
| JP2021072857A Active JP7149370B2 (ja) | 2013-09-23 | 2021-04-22 | ヒト化シグナル調節タンパク質遺伝子を有する非ヒト動物 |
Country Status (28)
| Country | Link |
|---|---|
| US (9) | US9193977B2 (enExample) |
| EP (5) | EP3434101B1 (enExample) |
| JP (4) | JP6453893B2 (enExample) |
| KR (2) | KR102407354B1 (enExample) |
| CN (2) | CN105592695B (enExample) |
| AU (3) | AU2014321187B2 (enExample) |
| CA (1) | CA2925564C (enExample) |
| CY (1) | CY1121410T1 (enExample) |
| DK (4) | DK4269430T3 (enExample) |
| ES (4) | ES2959333T3 (enExample) |
| FI (2) | FI4269430T3 (enExample) |
| HR (3) | HRP20251062T1 (enExample) |
| HU (3) | HUE042412T2 (enExample) |
| IL (4) | IL297607B2 (enExample) |
| LT (3) | LT3175706T (enExample) |
| MX (1) | MX368931B (enExample) |
| NZ (1) | NZ717817A (enExample) |
| PH (1) | PH12016500342A1 (enExample) |
| PL (3) | PL3434101T3 (enExample) |
| PT (4) | PT3175706T (enExample) |
| RS (3) | RS58365B1 (enExample) |
| RU (2) | RU2018136614A (enExample) |
| SG (3) | SG10201801326PA (enExample) |
| SI (3) | SI4269430T1 (enExample) |
| SM (3) | SMT202300287T1 (enExample) |
| TR (1) | TR201901782T4 (enExample) |
| WO (1) | WO2015042557A1 (enExample) |
| ZA (1) | ZA201601138B (enExample) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2700852T3 (es) | 2009-10-06 | 2019-02-19 | Regeneron Pharma | Ratones modificados genéticamente e injerto |
| CN105861553B (zh) | 2011-02-15 | 2020-08-14 | 再生元制药公司 | 人源化m-csf小鼠 |
| IL307969B1 (en) | 2012-09-07 | 2025-10-01 | Regeneron Pharma | Genetically modified non-human animals and methods of using them |
| CA2887706C (en) | 2012-11-05 | 2022-08-02 | Regeneron Pharmaceuticals | Genetically modified non-human animals and methods of use thereof |
| RU2018136614A (ru) * | 2013-09-23 | 2018-11-27 | Регенерон Фармасьютикалс, Инк. | Отличные от человека животные с гуманизированным геном сигнального регуляторного белка |
| TR201904342T4 (tr) | 2013-10-15 | 2019-05-21 | Regeneron Pharma | Hümani̇ze il-15 hayvanlar |
| EP3071024B1 (en) | 2013-11-19 | 2018-09-05 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized b-cell activating factor gene |
| ES2794942T3 (es) | 2014-04-08 | 2020-11-19 | Regeneron Pharma | Animales no humanos que tienen receptores Fc-gamma humanizados |
| NO2785538T3 (enExample) | 2014-05-07 | 2018-08-04 | ||
| DK3145307T3 (en) | 2014-05-19 | 2019-04-15 | Regeneron Pharma | RE-MODIFIED NON-HUMAN ANIMALS EXPRESSING HUMAN EPO |
| SG11201609638RA (en) | 2014-06-19 | 2016-12-29 | Regeneron Pharma | Non-human animals having a humanized programmed cell death 1 gene |
| PL3223605T3 (pl) | 2014-11-24 | 2021-04-19 | Regeneron Pharmaceuticals, Inc. | Zwierzęta inne niż ludzie eksprymujące humanizowany kompleks CD3 |
| DK3466255T3 (da) | 2014-12-05 | 2021-05-03 | Regeneron Pharma | Ikke-humane dyr med en humaniseret klynge af differentiering af 47-gen |
| ES2841353T3 (es) | 2014-12-09 | 2021-07-08 | Regeneron Pharma | Animales no humanos que tienen un gen del grupo de diferenciación 274 humanizado |
| CN113424798B (zh) * | 2015-04-13 | 2023-01-13 | 再生元制药公司 | 人源化SIRPα-IL15敲入小鼠及其使用方法 |
| CN104904661B (zh) * | 2015-06-05 | 2018-07-24 | 杭州正因生物技术有限公司 | 一种人源化小鼠 |
| IL256989B (en) | 2015-08-07 | 2022-08-01 | Alx Oncology Inc | Constructs with a sirp-alpha site or a variant thereof |
| HUE054612T2 (hu) | 2015-11-20 | 2021-09-28 | Regeneron Pharma | Humanizált limfocitaaktiváló gén 3-t tartalmazó nem-humán állatok |
| US10582702B2 (en) | 2016-02-04 | 2020-03-10 | Regeneron Pharmaceuticals, Inc. | Non-human animals having an engineered ANGPTL8 gene |
| SG10202001578RA (en) | 2016-02-29 | 2020-04-29 | Regeneron Pharma | Rodents having a humanized tmprss gene |
| CN108467873B (zh) | 2017-03-17 | 2020-03-13 | 百奥赛图江苏基因生物技术有限公司 | 一种cd132基因缺失的免疫缺陷动物模型的制备方法及应用 |
| WO2018177441A1 (en) | 2017-03-31 | 2018-10-04 | Beijing Biocytogen Co., Ltd | GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC SIRPα |
| CN108588126B (zh) | 2017-03-31 | 2020-04-10 | 北京百奥赛图基因生物技术有限公司 | Cd47基因人源化改造动物模型的制备方法及应用 |
| CN109136261B (zh) | 2017-06-19 | 2021-03-16 | 百奥赛图(北京)医药科技股份有限公司 | 人源化cd28基因改造动物模型的制备方法及应用 |
| WO2018233608A1 (en) * | 2017-06-19 | 2018-12-27 | Beijing Biocytogen Co., Ltd | Genetically modified non-human animal with human or chimeric cd28 |
| EP3585159B1 (en) | 2017-07-31 | 2025-05-14 | Regeneron Pharmaceuticals, Inc. | Method of testing the ability of a crispr/cas9 nuclease to modify a target genomic locus in vivo, by making use of a cas-transgenic mouse or rat which comprises a cas9 expression cassette in its genome |
| MX2020001177A (es) | 2017-07-31 | 2020-09-25 | Regeneron Pharma | Animales no humanos reporteros de crispr y usos de los mismos. |
| CA3071712C (en) * | 2017-09-29 | 2023-02-14 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized ttr locus and methods of use |
| US11419318B2 (en) | 2017-11-30 | 2022-08-23 | Regeneran Pharmaceuticals, Inc. | Genetically modified rat comprising a humanized TRKB locus |
| AU2019239880B2 (en) | 2018-03-19 | 2023-11-30 | Regeneron Pharmaceuticals, Inc. | Transcription modulation in animals using CRISPR/Cas systems |
| JP7328243B2 (ja) | 2018-03-26 | 2023-08-16 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 治療薬を試験するためのヒト化げっ歯類 |
| IL279321B2 (en) | 2018-07-10 | 2025-05-01 | Univ Kobe Nat Univ Corp | Antibody against SIRPalpha |
| SG11202011284RA (en) | 2018-07-16 | 2020-12-30 | Regeneron Pharma | Non-human animal models of ditra disease and uses thereof |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| WO2020160285A1 (en) * | 2019-02-01 | 2020-08-06 | The Board Of Trustees Of The Leland Stanford Junior University | SIRPα EXPRESSION ON T CELLS IS A BIOMARKER FOR FUNCTIONAL T CELLS DURING EXHAUSTION |
| CN117178959A (zh) | 2019-04-04 | 2023-12-08 | 瑞泽恩制药公司 | 包括人源化凝血因子12基因座的非人动物 |
| KR20220044904A (ko) | 2019-05-31 | 2022-04-12 | 알렉소 온콜로지 인크. | 면역 관문 억제제와 병용하는 sirp 알파 fc 융합으로 암을 치료하는 방법 |
| JP7610339B2 (ja) | 2019-06-04 | 2025-01-08 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ベータスリップ変異を有するヒト化ｔｔｒ遺伝子座を含む非ヒト動物と使用方法 |
| BR112021022722A2 (pt) | 2019-06-07 | 2022-01-04 | Regeneron Pharma | Animal não humano, célula de animal não humana, genoma de animal não humano, gene de albumina animal não humana humanizada, vetor de alvejamento, método de avaliação da atividade de um reagente, e, método de otimização da atividade de um reagente |
| US20230058049A1 (en) * | 2019-12-31 | 2023-02-23 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | GENETICALLY MODIFIED IMMUNODEFICIENT NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC SIRPa/CD47 |
| KR20220133248A (ko) | 2020-01-28 | 2022-10-04 | 리제너론 파마슈티칼스 인코포레이티드 | 인간화 pnpla3 좌위를 포함하는 비-인간 동물 및 사용 방법 |
| CA3167557A1 (en) | 2020-04-21 | 2021-10-28 | Davor Frleta | Non-human animals having a humanized cxcl13 gene |
| WO2022140221A1 (en) | 2020-12-21 | 2022-06-30 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized tslp gene, a humanized tslp receptor gene, and/or a humanized il7ra gene |
| CA3216908A1 (en) | 2021-05-13 | 2022-11-17 | ALX Oncology Inc. | Combination therapies for treating cancer |
| US20250143272A1 (en) * | 2022-01-25 | 2025-05-08 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Genetically modified non-human animal with human or chimeric nkp46 |
| US20240102045A1 (en) | 2022-07-19 | 2024-03-28 | Regeneron Pharmaceuticals, Inc. | Vectors, genetically modified cells, and genetically modified non-human animals comprising the same |
| US20240224964A9 (en) | 2022-09-29 | 2024-07-11 | Regeneron Pharmaceuticals, Inc. | Correction of hepatosteatosis in humanized liver animals through restoration of il6/il6r/gp130 signaling in human hepatocytes |
| AU2024304358A1 (en) | 2023-06-16 | 2025-11-06 | Regeneron Pharmaceuticals, Inc. | Vectors, genetically modified cells, and genetically modified non-human animals comprising the same |
| WO2025171307A1 (en) | 2024-02-08 | 2025-08-14 | Regeneron Pharmaceuticals, Inc. | Vectors, genetically modified cells, and genetically modified non-human animals comprising the same |
| WO2025212991A1 (en) | 2024-04-05 | 2025-10-09 | Regeneron Pharmaceuticals, Inc. | Rodent models of disease |
| WO2025250495A1 (en) | 2024-05-28 | 2025-12-04 | Regeneron Pharmaceuticals, Inc. | Acceleration of human hepatocyte engraftment in humanized liver animals by supplementing paracrine ligands or agonists that activate human liver regeneration signals |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5149635A (en) * | 1986-09-12 | 1992-09-22 | Abbott Biotech, Inc. | Messenger RNA stabilization in animal cells |
| TR200000669T2 (tr) * | 1997-09-12 | 2000-08-21 | Apotech R & D Sa | Büyüme etkinliğine sahip yeni bir protein-APRIL. |
| US6586251B2 (en) | 2000-10-31 | 2003-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| ES2364335T3 (es) * | 2003-12-24 | 2011-08-31 | G2 Inflammation Pty Ltd | Mamífero no humano transgénico que comprende un polinucleótido que codifica el c5ar humano o humanizado. |
| ES2667169T3 (es) | 2004-10-19 | 2018-05-09 | Regeneron Pharmaceuticals, Inc. | Método para generar un animal no humano homocigótico para una modificación genética |
| WO2006128163A2 (en) | 2005-05-27 | 2006-11-30 | Memory Pharmaceuticals Corp. | Transgenic alzheimer's mouse model vectors and uses thereof |
| US20070028316A1 (en) * | 2005-06-02 | 2007-02-01 | Xiaoxia Li | Transgenic non-human Act1-deficient mammals and uses thereof |
| JP2011500005A (ja) * | 2007-10-11 | 2011-01-06 | ユニバーシティー ヘルス ネットワーク | ヒト造血幹細胞の生着を増加させるためのＳＩＲＰα−ＣＤ４７相互作用の調節およびそのための化合物 |
| EP2262898B1 (en) | 2008-03-07 | 2018-01-24 | Regeneron Pharmaceuticals, Inc. | Es cell-derived mice from diploid host embryo injection |
| RU2425880C2 (ru) * | 2009-07-30 | 2011-08-10 | Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН | Способ получения трансгенных мышей |
| ES2700852T3 (es) | 2009-10-06 | 2019-02-19 | Regeneron Pharma | Ratones modificados genéticamente e injerto |
| US9402377B2 (en) * | 2010-09-20 | 2016-08-02 | Yale University | Human SIRPAalpha transgenic animals and their methods of use |
| EP2675901B1 (en) * | 2011-02-14 | 2018-05-30 | Revivicor, Inc. | Genetically modified pigs for xenotransplantation of vascularized xenografts and derivatives thereof |
| CN105861553B (zh) * | 2011-02-15 | 2020-08-14 | 再生元制药公司 | 人源化m-csf小鼠 |
| HUE035652T2 (en) | 2011-10-28 | 2018-05-28 | Regeneron Pharma | Genetically modified major histocompatibility complex mice |
| DK2663575T3 (en) * | 2011-10-28 | 2014-12-15 | Regeneron Pharma | HUMANIZED IL-6 and IL-6 receptor |
| KR102113108B1 (ko) | 2011-10-28 | 2020-05-20 | 리제너론 파아마슈티컬스, 인크. | 키메라 주요 조직적합성 복합체 （ｍｈｃ） 제ｉｉ부류 분자들을 발현하는 유전자전이 마우스 |
| US8962913B2 (en) | 2012-06-18 | 2015-02-24 | Regeneron Pharmaceuticals, Inc. | Humanized IL-7 rodents |
| IL307969B1 (en) | 2012-09-07 | 2025-10-01 | Regeneron Pharma | Genetically modified non-human animals and methods of using them |
| CA2887706C (en) | 2012-11-05 | 2022-08-02 | Regeneron Pharmaceuticals | Genetically modified non-human animals and methods of use thereof |
| WO2014130671A1 (en) | 2013-02-20 | 2014-08-28 | Regeneron Pharmaceuticals, Inc. | Mice expressing humanized t-cell co-receptors |
| KR102211267B1 (ko) | 2013-02-22 | 2021-02-04 | 리제너론 파아마슈티컬스, 인크. | 사람화된 주요 조직적합성 복합체를 발현하는 마우스 |
| RU2018136614A (ru) | 2013-09-23 | 2018-11-27 | Регенерон Фармасьютикалс, Инк. | Отличные от человека животные с гуманизированным геном сигнального регуляторного белка |
| CA2984413A1 (en) * | 2015-04-30 | 2016-11-03 | Institute Of Immunology Co., Ltd. | Transgenic non-human animal expressing human specific molecule and human fc.gamma. receptor family |
-
2014
- 2014-09-23 RU RU2018136614A patent/RU2018136614A/ru not_active Application Discontinuation
- 2014-09-23 JP JP2016544055A patent/JP6453893B2/ja active Active
- 2014-09-23 RU RU2016110462A patent/RU2671166C2/ru active
- 2014-09-23 HR HRP20251062TT patent/HRP20251062T1/hr unknown
- 2014-09-23 PL PL18192264.2T patent/PL3434101T3/pl unknown
- 2014-09-23 SI SI201432112T patent/SI4269430T1/sl unknown
- 2014-09-23 DK DK23185050.4T patent/DK4269430T3/da active
- 2014-09-23 SI SI201431078T patent/SI3175706T1/sl unknown
- 2014-09-23 ES ES18192264T patent/ES2959333T3/es active Active
- 2014-09-23 WO PCT/US2014/056910 patent/WO2015042557A1/en not_active Ceased
- 2014-09-23 LT LTEP16206491.9T patent/LT3175706T/lt unknown
- 2014-09-23 ES ES14781783.7T patent/ES2624614T3/es active Active
- 2014-09-23 LT LTEP23185050.4T patent/LT4269430T/lt unknown
- 2014-09-23 SM SM20230287T patent/SMT202300287T1/it unknown
- 2014-09-23 EP EP18192264.2A patent/EP3434101B1/en active Active
- 2014-09-23 IL IL297607A patent/IL297607B2/en unknown
- 2014-09-23 HU HUE16206491A patent/HUE042412T2/hu unknown
- 2014-09-23 PT PT16206491T patent/PT3175706T/pt unknown
- 2014-09-23 RS RS20190162A patent/RS58365B1/sr unknown
- 2014-09-23 SG SG10201801326PA patent/SG10201801326PA/en unknown
- 2014-09-23 PL PL23185050.4T patent/PL4269430T3/pl unknown
- 2014-09-23 HR HRP20231121TT patent/HRP20231121T1/hr unknown
- 2014-09-23 DK DK16206491.9T patent/DK3175706T3/en active
- 2014-09-23 DK DK14781783.7T patent/DK2922394T3/en active
- 2014-09-23 DK DK18192264.2T patent/DK3434101T5/da active
- 2014-09-23 EP EP23185050.4A patent/EP4269430B1/en active Active
- 2014-09-23 PT PT147817837T patent/PT2922394T/pt unknown
- 2014-09-23 RS RS20250788A patent/RS67091B1/sr unknown
- 2014-09-23 SG SG10201902547SA patent/SG10201902547SA/en unknown
- 2014-09-23 EP EP25183430.5A patent/EP4635977A2/en active Pending
- 2014-09-23 SI SI201432041T patent/SI3434101T1/sl unknown
- 2014-09-23 MX MX2016003636A patent/MX368931B/es active IP Right Grant
- 2014-09-23 AU AU2014321187A patent/AU2014321187B2/en active Active
- 2014-09-23 EP EP16206491.9A patent/EP3175706B1/en active Active
- 2014-09-23 KR KR1020227006825A patent/KR102407354B1/ko active Active
- 2014-09-23 PL PL16206491T patent/PL3175706T3/pl unknown
- 2014-09-23 CA CA2925564A patent/CA2925564C/en active Active
- 2014-09-23 CN CN201480051997.1A patent/CN105592695B/zh active Active
- 2014-09-23 TR TR2019/01782T patent/TR201901782T4/tr unknown
- 2014-09-23 CN CN201810267662.3A patent/CN108441497B/zh active Active
- 2014-09-23 HU HUE23185050A patent/HUE072332T2/hu unknown
- 2014-09-23 NZ NZ717817A patent/NZ717817A/en unknown
- 2014-09-23 HU HUE18192264A patent/HUE063376T2/hu unknown
- 2014-09-23 PT PT231850504T patent/PT4269430T/pt unknown
- 2014-09-23 FI FIEP23185050.4T patent/FI4269430T3/fi active
- 2014-09-23 US US14/493,745 patent/US9193977B2/en active Active
- 2014-09-23 SM SM20190067T patent/SMT201900067T1/it unknown
- 2014-09-23 ES ES16206491T patent/ES2710282T3/es active Active
- 2014-09-23 KR KR1020167008334A patent/KR102370419B1/ko active Active
- 2014-09-23 SM SM20250280T patent/SMT202500280T1/it unknown
- 2014-09-23 PT PT181922642T patent/PT3434101T/pt unknown
- 2014-09-23 EP EP14781783.7A patent/EP2922394B1/en active Active
- 2014-09-23 ES ES23185050T patent/ES3037239T3/es active Active
- 2014-09-23 SG SG11201601184UA patent/SG11201601184UA/en unknown
- 2014-09-23 FI FIEP18192264.2T patent/FI3434101T3/fi active
- 2014-09-23 LT LTEP18192264.2T patent/LT3434101T/lt unknown
- 2014-09-23 RS RS20230816A patent/RS64573B1/sr unknown
- 2014-10-17 US US14/516,606 patent/US9127292B2/en active Active
-
2015
- 2015-10-14 US US14/882,531 patent/US9462794B2/en active Active
-
2016
- 2016-02-18 ZA ZA2016/01138A patent/ZA201601138B/en unknown
- 2016-02-18 IL IL244187A patent/IL244187B/en active IP Right Grant
- 2016-02-19 PH PH12016500342A patent/PH12016500342A1/en unknown
- 2016-09-13 US US15/263,916 patent/US9700027B2/en active Active
-
2017
- 2017-06-06 US US15/615,298 patent/US9901083B2/en active Active
-
2018
- 2018-01-10 US US15/866,632 patent/US10206379B2/en active Active
- 2018-11-12 IL IL262958A patent/IL262958A/en active IP Right Grant
- 2018-12-13 JP JP2018233311A patent/JP6665269B2/ja active Active
-
2019
- 2019-01-03 US US16/238,589 patent/US10426146B2/en active Active
- 2019-02-05 HR HRP20190227TT patent/HRP20190227T1/hr unknown
- 2019-02-07 CY CY20191100163T patent/CY1121410T1/el unknown
- 2019-08-15 US US16/541,334 patent/US11019810B2/en active Active
-
2020
- 2020-02-19 JP JP2020026122A patent/JP6875573B2/ja active Active
- 2020-11-12 IL IL278679A patent/IL278679B2/en unknown
- 2020-12-08 AU AU2020286187A patent/AU2020286187B2/en active Active
-
2021
- 2021-04-22 JP JP2021072857A patent/JP7149370B2/ja active Active
- 2021-04-27 US US17/241,171 patent/US12161097B2/en active Active
-
2024
- 2024-09-02 AU AU2024216527A patent/AU2024216527A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019047818A5 (enExample) | ||
| Banerjee et al. | Targeted ablation of nesprin 1 and nesprin 2 from murine myocardium results in cardiomyopathy, altered nuclear morphology and inhibition of the biomechanical gene response | |
| WO2015042557A4 (en) | Non-human animals having a humanized signal-regulatory protein gene | |
| JP2019022518A5 (enExample) | ||
| JP2018500012A5 (enExample) | ||
| HRP20200613T1 (hr) | Neljudske životinje koje imaju humanizirani gen 1 za programiranu staničnu smrt | |
| Kim et al. | S100A9 knockout decreases the memory impairment and neuropathology in crossbreed mice of Tg2576 and S100A9 knockout mice model | |
| JP2017514501A5 (enExample) | ||
| CN113940309B (zh) | 一种慢性萎缩性胃炎病变的模拟方法及小鼠造模鉴定方法 | |
| JP2017500854A (ja) | ポリペプチド、核酸およびその使用 | |
| Du et al. | A point mutation (R192H) in the C-terminus of human cardiac troponin I causes diastolic dysfunction in transgenic mice | |
| Wang et al. | Translocator protein (Tspo) gene promoter-driven green fluorescent protein synthesis in transgenic mice: an in vivo model to study Tspo transcription | |
| CN102712687A (zh) | 作为补体激活的抑制剂的masp同种型 | |
| Leclère et al. | Otoferlin as a multirole Ca2+ signaling protein: from inner ear synapses to cancer pathways | |
| JP2019506897A5 (enExample) | ||
| JPWO2002039813A1 (ja) | Ｐｄ−１欠損マウスおよびその用途 | |
| CN102176914B (zh) | 用于诊断和治疗癌症的vhz | |
| JP2021508236A5 (enExample) | ||
| CN106994185A (zh) | Tie2对视网膜及其他组织中静脉血管的保护作用及应用 | |
| Zupkovitz et al. | Phylogenetic analysis and expression profiling of the Klotho gene family in the short-lived African killifish Nothobranchius furzeri | |
| CN117210497A (zh) | Abcg4基因在构建脑动脉粥样硬化伴肺部增大小鼠模型中的应用 | |
| WO2002064731A2 (fr) | Sequences impliquees dans les phenomenes de suppression tumorale reversion tumorale apoptose et/ou resistance aux virus et leur utilisation comme medicaments | |
| JP2023543232A (ja) | ヘッジホッグシグナル伝達経路の活性化のための強力な結合剤 | |
| JP2002504806A (ja) | 糖尿病媒介タンパク質およびその治療的使用 | |
| JP5971966B2 (ja) | Ｔｄｐ−４３の凝集体が蓄積する疾患の発症リスクを予測する方法、診断薬及び治療薬 |